Amgen Reports Phase 2 MT103-211 Results for Blincyto in Relapsed/Refractory ALL

Amgen today announced results from the Phase 2 MT103-211 trial evaluating Blincyto (blinatumomab) in adults with relapsed or refractory B-cell acute lymphoblastic leukemia. The trial demonstrated a complete remission rate of 43%, with a median overall survival of 6.1 months. These results led to FDA accelerated approval of Blincyto for relapsed/refractory ALL.